- Email: [email protected]
Platelet arachidonic acid metabolism in angina pectoris
160
THROMBOSIS
RESEARCH
Suppl . VI,
1986
316
DOUBLE-BLIND CLINICAL TRIAL OF TICLOPIDINE VERSUS PLACEBO IN PERIPHERAL ATHEROSCLEROTIC DISEASE OF THE LEGS M. CLOAREC, Ph. CAILLARD, X. MOUREN - Hgpital TENON - 75020 PARIS - FRANCE.
132 patients with peripheral arterial disease of the legs were randomized in a 6-month double blind clinical trial to compare efficacy and safety of an antiplatelet agent, Ticlopidine (Ti) 250 mg. twice daily versus placebo (Pl). Prior to entering the study, These patients had followed up for at least one year, with compensated stabilized risk factors. Clinical examinations, doppler investigations and treadmill tests were carried out at 2 months intervals. No initial significant difference was detected between the two groups. At the end of the trial, 53 patients (84 W) reported improvement in the Ti group and 28 patients (44 %) in the Pl group (P value < 001). Hemodynamic evaluations (Doppler) showed best results in the Ti group (35 pts ; 56 %) than in the Pl group (19 pts ; 30 X) (p value < 01). The initial value of claudication distance was doubled in the sixth month in the Ti group for 46 patients (73 X) and in the Pl group for 18 patients (30 %) (p value < 001). No severe side effect was reported in either group.
317 PLATELET/WKHImIC ACIDtCT/X?QLIsM IN ANGINA PECTCRIS Gemini G.F. Neri Semeri G.G., Abbate R., PanettaA., Pinto S., FavillaS., PriscoD. and -ClinicaMedica I, Universityof Florence,Florence,Italy. Thrcnboxane (TX)A2 generation (maasuml as TxB2 by RIA) and 1-W arachidonicacid (AA) metabolism (HPLC)by plateletsfran diffemt subsetsof angina1patientsand controls were investigated. Patientssufferingfran angina1attacksat rest (activespontaneousangina -ASpA) (n=l5) had a significtitly increasedgenerationof TxA2in ccnpariscmto the other groupsof patients: patientswith stableeffortangina (EA) (n=8; p
THROMBOSIS
RESEARCH
Suppl . VI,
1986
316
DOUBLE-BLIND CLINICAL TRIAL OF TICLOPIDINE VERSUS PLACEBO IN PERIPHERAL ATHEROSCLEROTIC DISEASE OF THE LEGS M. CLOAREC, Ph. CAILLARD, X. MOUREN - Hgpital TENON - 75020 PARIS - FRANCE.
132 patients with peripheral arterial disease of the legs were randomized in a 6-month double blind clinical trial to compare efficacy and safety of an antiplatelet agent, Ticlopidine (Ti) 250 mg. twice daily versus placebo (Pl). Prior to entering the study, These patients had followed up for at least one year, with compensated stabilized risk factors. Clinical examinations, doppler investigations and treadmill tests were carried out at 2 months intervals. No initial significant difference was detected between the two groups. At the end of the trial, 53 patients (84 W) reported improvement in the Ti group and 28 patients (44 %) in the Pl group (P value < 001). Hemodynamic evaluations (Doppler) showed best results in the Ti group (35 pts ; 56 %) than in the Pl group (19 pts ; 30 X) (p value < 01). The initial value of claudication distance was doubled in the sixth month in the Ti group for 46 patients (73 X) and in the Pl group for 18 patients (30 %) (p value < 001). No severe side effect was reported in either group.
317 PLATELET/WKHImIC ACIDtCT/X?QLIsM IN ANGINA PECTCRIS Gemini G.F. Neri Semeri G.G., Abbate R., PanettaA., Pinto S., FavillaS., PriscoD. and -ClinicaMedica I, Universityof Florence,Florence,Italy. Thrcnboxane (TX)A2 generation (maasuml as TxB2 by RIA) and 1-W arachidonicacid (AA) metabolism (HPLC)by plateletsfran diffemt subsetsof angina1patientsand controls were investigated. Patientssufferingfran angina1attacksat rest (activespontaneousangina -ASpA) (n=l5) had a significtitly increasedgenerationof TxA2in ccnpariscmto the other groupsof patients: patientswith stableeffortangina (EA) (n=8; p